Details of the Drug

General Information of Drug (ID: DMXT6YT)

Drug Name

ALXN2030

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small interfering RNA

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C3 messenger RNA (C3 mRNA)	TTXA5VP	CO3_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05501717) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alexion